secwatch / observer

8-K filed June 1, 2026, 4:00 PM ET CIK 0001847513

other material confidence high sentiment negative materiality 0.90

Corner Growth Acquisition Corp. 2 to liquidate and dissolve after failing to complete business combination

CORNER GROWTH ACQUISITION CORP. 2

Board determined an initial business combination cannot be completed; liquidation and dissolution commenced.
Public shares will be redeemed at per-share price equal to trust account deposits (less up to $100k for expenses).
Company will cease all operations except those required for winding up.
Redemption extinguishes public shareholders' rights, subject to Cayman law and creditor claims.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001477932-26-003548
form_type: 8-K
ticker: null
cik: 0001847513
company_name: CORNER GROWTH ACQUISITION CORP. 2
filed_at: 2026-06-01T20:00:34+00:00
discovered_at: 2026-06-01T20:01:00.607413+00:00
generated_at: 2026-06-01T20:01:15.660638+00:00
sec_items: ["8.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001477932-26-003548
json_url: https://secwatch.observer/filing/0001477932-26-003548.json
markdown_url: https://secwatch.observer/filing/0001477932-26-003548.md
text_url: https://secwatch.observer/filing/0001477932-26-003548.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1847513/000147793226003548/0001477932-26-003548-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1847513/000147793226003548/corner_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Corner Growth Acquisition Corp.

Corner Growth Acquisition Corp. to liquidate; will redeem public shares

Corner Growth Acquisition Corp. June 1, 2026, 4:00 PM ET other_material Items 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

SMMT

Ivonescimab: 70.8% ORR in mCRC Phase II; HARMONi-6 OS HR 0.66 vs tislelizumab

Summit Therapeutics Inc. June 1, 2026, 6:57 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001477932-26-003548

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.